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The dopamine transporter (DAT) is a plasma membrane protein that clears extraneuronal 
dopamine (DA) and thus controls the spatio-temporal dynamics of dopaminergic 
neurotransmission.  Also, DAT is the major target for psychostimulant substrates, 
amphetamine (AMPH) and methamphetamine (METH), and psychostimulant uptake 
blocker, cocaine (COC). DAT is a phosphoprotein with both the N- and C-termini facing 
toward the cytosol, with multiple phosphorylation sites on the N-terminus. DAT has a 
closely spaced 6-serine cluster on the distal N-terminus that is phosphorylated in a 
protein kinase C (PKC)-dependent manner and a recently identified proline-directed site, 
Thr (T) 53, that is phosphorylated in vitro by the MAP kinases ERK, JNK and p38. 
Current studies indicate that COC and AMPH impact DAT regulatory properties 
including uptake activity and surface expression. Although the mechanism of drug action 
on DAT is not completely known, phosphorylation conditions of DAT have been found 
to be associated with altered surface expression and activity of DAT. In this study, we 
examined the effect of several psychostimulant drugs on the phosphorylation of DAT 
using a newly developed phospho-specific antibody against phosphorylated T53 (pT53) 
on DAT. A detailed analysis of pT53 on DAT was performed in LLC-PK1 cells 
expressing rat DAT (rDAT), rat striatal synaptosomes and in vivo in male Sprague-
Dawley rats. Our studies revealed psychostimulant substrates but not uptake blockers 
significantly stimulated pT53. Pretreatment with COC blocked the AMPH stimulation of 
pT53 indicating that AMPH stimulates pT53 in a DAT-dependent manner. In rat striatal 




Subcutaneous injections of METH in rats stimulated pT53 in a time-dependent manner. 
Our study demonstrates that the proline-directed phosphorylation site, pT53 is subject to 
differential regulation by psychostimulant drugs. Prolyl cis-trans isomerase, Pin1 
catalyzes the cis-trans isomerization of pThr-Pro peptides allowing the dephosphorylation 
by conformation-specific phosphatases. We investigated the regulation of pT53 by Pin1 
using Juglone (Jug), a small molecule inhibitor of Pin1. Treatment with Jug in LLC-PK1 
rDAT cells and rat striatal synaptosomes revealed significant stimulation of pT53. Jug 
treatment enhances [3H]DA efflux from rat striatal synaptosomes. ELISA indicated 
interaction between the N-terminus of DAT and Pin1. This is the first evidence of DAT 
regulation by Pin1. Our study demonstrates the regulation of DAT pT53 by Pin1 and 












  The brain governs physiological and psychological processes of the human body 
through a highly complex and coordinated network composed of billions of neurons. 
Each neuron communicates with other neurons by a process known as neurotransmission. 
Neurotransmission occurs at specialized neuronal junctions called synapses. This process 
involves the release of neurotransmitter from the presynaptic neuron, which is recognized 
by the receptors on the surface of the postsynaptic neuron. 
  Synaptic vesicles that serve as the storage pool of the neurotransmitters are 
docked at the active zones of presynaptic neuronal membranes and primed for the release 
of neurotransmitter. Neurotransmission occurs in response to the depolarization of the 
presynaptic neuronal membrane upon arrival of the action potential.  The action potential 
that originates in the cell body of the neuron travels down the axon terminal and opens 
Ca2+ channels. The increase in Ca2+ triggers the fusion of the primed synaptic vesicles 
with the neuronal membrane to release their contents into the synaptic cleft. The released 
neurotransmitter is sensed by the receptors on the postsynaptic neuron propagating the 
signal to the connecting neuron. Neurotransmission is terminated by clearance of the 




degradation, diffusion and or re-uptake of the released neurotransmitter in to presynaptic 
neuron by neurotransmitter-specific transporter proteins or re-uptake into a neighboring 
glial cell [1].   
Dopamine and dopaminergic system 
!
  Dopamine (DA) is synthesized in dopaminergic neurons from tyrosine. Tyrosine 
is also the precursor of other catecholamine neurotransmitters like norepinephrine (NE) 
and epinephrine. Initially DA was only considered as a mere precursor of NE and 
epinephrine. Later, neurotransmitter properties of DA were demonstrated and since then 
DA is regarded as a neurotransmitter which controls movement, reward-seeking 
behavior, emotion and cognition [2,3]. Dopaminergic neurons are present in the ventral 
tegmental area (VTA), the substantia nigra and the arcuate nucleus of the hypothalamus 
regions of the brain. There are four dopaminergic pathways, mesocortical, mesolimbic, 
nigrostriatal, and tuberoinfundibular (Fig.1). Among the four pathways, the mesolimbic 
pathway that connects the VTA of the mid brain to the nucleus accumbens in the striatum 




  Dopaminergic neurotransmission is terminated by various processes- uptake of 
DA by glial cells and dopaminergic neurons, degradation of DA by catechol-O-methyl 
transferase (COMT) and monoamine oxidase (MAO). The major process of 
dopaminergic signaling termination occurs by transporter proteins localized to the 











Figure 1. The four dopaminergic pathways 
Dopaminergic neurons extend from the ventral tegmental area (VTA), substantia nigra 
and mesobasal hypothalamus to the nucleus accumbens, prefrontal cortex, striatum and 
base of the hypothalamus. These neuronal projections form the mesolimbic, mesocortical, 














Image adapted from Okinawa Institute of Science and Technology with permission 

































transporters localized to the presynaptic neuronal membrane. The transporters are 
neurotransmitter-specific dopamine transporter (DAT) for DA, serotonin transporter 
(SERT) for serotonin, norepinephrine transporter (NET) for norepinephrine [5]. 
Primary target for psychostimulants 
!
  Psychostimulants like methamphetamine (METH), d-amphetamine (AMPH) 
(collectively referred to as amphetamines) and cocaine (COC) (Fig.3), have been a major 
threat to society. The strong reinforcing properties and the abuse potential of these drugs 
indicate the requirement for development of an effective medication to treat drug 
addiction. These psychostimulant drugs affect the neural circuitry and increase cravings 
for repeated drug use leading to addiction [6]. Understanding the molecular mechanisms 
of psychostimulant drugs for the development of therapeutic approach has been an active 
area of research. 
  The psychostimulants are known to elicit their actions primarily by altering 
dopaminergic homeostasis in the brain (Fig.2). In 1980s, a few studies implicated that 
dopamine-containing neurons in the forebrain projections and the ventral tagmentum of 
the brain region are crucial for the reinforcing properties of psychostimulant drugs like 
COC and AMPH [7]. Though the role of dopaminergic signaling in psychostimulant 
abuse was not completely established, pathology of the dopamine system was predicted 
as a potential target for psychostimulant action [4], [7]. The requirement of DAT and DA 











Figure 2. Representation of a dopaminergic synapse under physiological and pathological 
states 
A. Under physiological conditions, DA is recycled back into the presynaptic neuron by 
DAT where DA is transported into vesicles by VMAT and stored. B. In the presence of 
the DAT blocker, cocaine, the reuptake of DA into presynaptic neuron is prevented 
resulting in buildup of DA at the synapse. C. Amphetamines are DAT substrates, once 
inside the neuron, they also get transported via VMAT into vesicles and cause the release 
of DA increasing the cytosolic concentration of DA and cause non-vesicular release of 














Image courtesy, R. A. Espana and S. R. Jones, 2013 Presynaptic dopamine modulation by 
stimulant self-administration. Front. Biosci. (Schol. Ed)., vol. 5, pp. 261–76, with 
permission [8] 















Figure 3. Chemical structures of dopamine transporter substrates and cocaine 
Representation of chemical structures of dopamine transporter (DAT) substrates: 







































DAT knock out (KO) mice. Homozygous DAT KO mice displayed decreased DA uptake 
and highly compromised ability to clear the extraneuronal DA consistent with increased 
spontaneous locomotor activity [9]. This further led to the ‘dopamine hypothesis’, 
according to which, cocaine first binds to DAT and blocks DA uptake (Fig.2), which 
results in potentiation of dopaminergic neurotransmission in the limbic pathways. This 
ultimately leads to reinforcement of the behavior that is associated with the molecular 
events of cocaine binding and uptake inhibition [10].  
  COC is non-transportable through DAT [11], the psychostimulants and other 
therapeutic drugs that belong to this class are called blockers. DAT blockers that do not 
induce cocaine-like behavioral patterns such as benztropine (BZT) are termed atypical 
uptake blockers [12]. Along with the inhibition in DA uptake, DA receptors are also 
implicated in the reinforcement of COC [7]. 
  Amphetamines are also a prescribed medication for ADHD and depression. 
Amphetamines act in a complex fashion to impact DA signaling. In addition to uptake 
inhibition of DAT [13], AMPH also gets transported via DAT into the presynaptic 
neuron. Once inside the presynaptic neuron, AMPH causes reverse transport of DA via 
DAT (Fig.2). This process is also referred to as efflux. In addition, at higher 
concentrations, amphetamines are also known to diffuse through the membrane due to 
their hydrophobic nature. Pretreatment with COC blocks AMPH-stimulated DA efflux 
indicating that DAT-mediated entry of AMPH is required for the efflux mechanism [14, 
15]. The mechanism of DAT transport reversal by AMPH is proposed to occur by an 
exchange diffusion model. According to this model, AMPH gets transported into the 




DAT. AMPH also contributes to the increased synaptic DA concentration by depleting 
the secretory vesicle stores of DA. In addition, AMPH also inhibits MAO preventing the 
oxidation and inactivation of DA [16]. These mechanisms result in the increase in the 
cytosolic concentration of DA favoring the AMPH-stimulated efflux and contributing to 
oxidative damage. In addition to psychostimulant drugs, DAT also serves as a gateway 
for several environmental toxins like MPP+, which is derived from MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine) by MAO [17][18] (Fig.3). 
Structure 
!
  DAT, NET, and SERT along with transporters for other solutes like glycine and 
GABA are encoded by genes of the SLC6 (Solute Carrier 6) family. The members of the 
SLC6 family are expressed in a wide range of tissues with major distribution in the 
central nervous system (CNS) where they function to maintain homeostasis of  
neurotransmitters. These are secondary active transporters that utilize the electro-
chemical gradient generated by Na+/K+ ATPase to drive the symport of neurotransmitter 
and Na+ [19] [5] [20] [21]. 
  The cDNA of rat DAT was first cloned, transiently expressed and characterized 
for DA uptake activity in HeLa cells [22]. Human DAT (hDAT) is a 620 amino acid 
protein while rat DAT (rDAT) is comprised of 619 amino acids, and both contain 12 
transmembrane (TM) domains with both N and C termini facing towards the cytosol. The 
primary sequence of DAT has revealed sites for glycosylation on the extracellular loop 
which were later observed to have a role in regulating function, surface expression [20] 




glycosylation sites, the three dimensional structure of DAT was not known until the 
crystallization of a bacterial homologue, a leucine transporter (Leu T) from Auifex 
aeolicus [24]. This bacterial homologue shares 20% sequence homology with DAT. Leu 
T crystal structure displays a pseudo-symmetrical arrangement of TMs 1-5 and TMs 6-10 
with TMs 1, 3, 6 and 8 constituting the core of the transporter forming the substrate 
translocation pathway. In addition to the information from the Leu T crystal structure, 
drosophila DAT (dDAT) crystal structure was recently reported [25]. 
DAT is proposed to function by an alternating access mechanism [26] in which 
DAT undergoes a series of conformational changes from an outward-facing 
conformational state to an inward-facing conformation (Fig.4). The different 
conformations of DAT are stabilized by different gates, which allow access to DAT from 
either the extracellular or intracellular side [27]. The outward facing conformation of 
DAT in which the extracellular gate is open, allows the substrate to bind from the 
extracellular side. The extracellular gate is formed by a salt bridge between the amino 
acids R85 on TM1 and D476 on TM10.  The intracellular gate formed by R60 on the N-
terminus and D436 on TM8 opens to form the inward-facing state [24][28]. This 
conformation allows the release of substrate to the intracellular milieu. The substrate-
bound transporter with both the extracellular and the intracellular gates closed results in 











Figure 4. Alternating access model of SLC6 transporters 
The figure depicts the series of conformational states in an alternating access model of 
SLC6 transporters. The outward-facing conformation allows substrate and sodium ion 
binding to the transporter. The occluded conformation is then followed representing a 
state in which, the extracellular and the intracellular gates are closed. The inward facing 
conformation with the intracellular gate open allows the release of the substrate and the 














Image courtesy, A. S. Kristensen, J. Andersen, T. N. Jørgensen, L. Sørensen, J. Eriksen, 
C. J. Loland, K. Strømgaard, and U. Gether, 2011 SLC6 neurotransmitter transporters 
structure, function, and regulation. Pharmacol. Rev., vol. 63, pp. 585–640, with 
permission [27]. 








All the gating residues are conserved in the SLC6 transporters [24]. Mutation of the 
gating residues in DAT has been shown to impact the conformational states of the 
transporter [28] [29]. The intracellular gating resides R60 and D436 in DAT, when 
mutated to R60A and D436A displayed significant decreases in Vmax for [3H]DA uptake 
[28]. The surface expression of both the mutants were comparable to WT DAT 
suggesting the decreased uptake was not due to altered surface expression but due to the 
impairment of the intracellular gating residues [28]. The Leu T crystal structure revealed 
the interaction of the intracellular gating residue, R60 with Y335 in TM6. Y335A DAT 
displayed reduced Vmax with no loss in surface expression compared to WT DAT 
indicating its prominent role in stabilizing the intracellular gate and hence DAT function 
[29].  
  The role and requirement of the following residues R60, D436 and Y335 in the 
intracellular gating mechanism has been further substantiated by Zn2+ coordination 
experiments. Zn2+ interacts with H193, H375 and E396 to stabilize the outward facing 
conformation of DAT [30]. The decreased uptake activities of R60A, D436A and Y335A 
DATs were rescued in the presence of Zn2+[28], [29]. This demonstrates the ability of 
Zn2+ to stabilize the outward facing conformation and facilitate the uptake activity in 
intracellular gate impaired DAT mutants. 
  In addition to the role of Zn2+ in stabilizing the outward open conformation of 
DAT, the dDAT crystal structure revealed the presence of cholesterol, which is 
hypothesized to stabilize DAT in an outward-open conformation [25]. This indicates that 




reported in dDAT structure was a kink in TM12 that resembles a latch facing away from 
the transporter which is predicted to potentially regulate DAT function [25].  
  The cytoplasmic tails, both N- and C-termini, are much shorter in both dDAT and 
the bacterial homologue Leu T leading to the lack of a resolved structure for these tails 
[24], [25]. Both tails are sites for several post-translational modifications and regulate 
various characteristics of the transporter while serving as sites of interaction for many 
binding partners. 
DAT interaction partners 
!
  DAT has been shown to interact and form complexes with various proteins, which 
in turn affect the function, phosphorylation, trafficking and, subcellular localization of 
DAT (Fig.5). DAT is a dynamic membrane protein that trafficks to and from the plasma 
membrane. Some of the proteins that interact with DAT include synaptic vesicular 
plasma membrane proteins and enzymes like PP2A, PKC β, RACK, Hic-5, synaptogyrin-
3, VMAT2, Syntaxin 1A (Syn 1A) [31]–[34].  
  Syn 1A, a SNARE protein was observed to decrease DAT uptake activity along 
with decreased surface expression in a heterologous system co-expressing DAT and Syn 
1A [35]. In addition, Syn 1A was also found to enhance AMPH-stimulated DA efflux 
[36]. This indicates the role of Syn 1A in regulating DAT function under physiological 
conditions and drug abused states. Membrane micro domain marker, Flotillin 1 (Flot 1) 
was recently identified as a protein required for PKC-triggered endocytosis of DAT that 
also favors AMPH-induced efflux in DA primary neurons without affecting DA uptake 











Figure 5. Representation of interaction partners of the dopamine transporter 
Figure represents the dopamine transporter embedded in a lipid bilayer with the post-
translational modifications on both N-terminal and C-terminal tails. The interaction 















Image courtesy, R. A. Vaughan and J. D. Foster, 2013 Mechanisms of dopamine 
transporter regulation in normal and disease states. Trends Pharmacol. Sci., vol. 34, no. 
9, pp. 489–96, [38].  






neurons) as a DAT interacting protein in a PKC regulated manner and required for PKC- 
triggered endocytosis of DAT [39]. AMPH is also known to impact the surface 
expression of DAT.  
  AMPH-induced internalization of DAT is observed in both heterologous 
expression system and rat striatal synaptosomal preparations [40]. Interestingly, in the 
early treatment times (60 sec) [41], amphetamines cause rapid increase in the surface 
expression of DAT in a heterologous expression system. Methamphetamine (METH) 
exposure redistributes dopamine from vesicles to the cytoplasm in dopamine neuronal 
cultures contributing to the formation of reactive species [42] and also triggers DAT 
complex formation [43]. Involvement of many players in DAT interaction and regulation 
appears that the system may have evolved with several backup or alternate mechanisms 
for monitoring DAT activity and surface expression under normal as well as under 
diseased or drug abused states accordingly. 
Regulation of DAT 
Phosphorylation 
!
  DAT has been shown to be regulated by various protein kinases including PKC, 
ERK, PKA, and CaMKII [44]–[47] with PKC regulation of DAT being the most 
extensively studied. In rat striatal tissue and cultured cells stably expressing hDAT or 
rDAT, both PKC activation with phorbol 12-myristate 13-acetate (PMA) [45] and 
inhibition of phosphatases with okadaic acid (OA) increases phosphorylation of DAT in a 












Figure 6. Schematic representation of the rat dopamine transporter 
 The figure shows the rat dopamine transporter with 12 transmembrane domains 
connected by extracellular and the intracellular loops with both N- and C-termini facing 
towards the cytoplasm. Known in vivo phosphorylation sites are represented in big light-
blue circles. Also depicted, in small light-blue circles, are predicted phosphorylation 
sites. Depicted in green is epitope 16 on the N-terminus and the palmitoylation site, in 






















expression systems have shown decreased Vmax with no change in affinity [45], [49]–
[51]. Down regulation of DAT activity in the presence of PKC activation is associated 
with decreased surface expression of DAT. PKC activation was demonstrated to localize 
DAT to recycling endosomes where it colocalizes with transferrin receptor [52]. A C-
terminal subdomain FREKLAYAIA, spanning amino acids 587-596 of DAT (Fig.6) was 
later implicated to be required for constitutive endocytosis and PKC-stimulated down 
regulation of DAT in PC12 cells and primary midbrain neurons. The sequence 
FREKLAYAIA is conserved among the other neurotransmitter transporters and was 
demonstrated to be required for a fellow SLC6 transporter, NET [53]. Further studies on 
this subdomain led to a proposed model that the residues in the first half of the 
FREKLAYAIA spanning residues 587-590 might act as a braking mechanism to control 
basal endocytosis, with PKC activation releasing the break resulting in enhanced 
endocytosis [54]. Although PCK-stimulated down regulation of DAT activity was 
thought to be mediated through phosphorylation of DAT, truncation of distal N-terminal 
serines displayed no effect on PKC-stimulated internalization, ruling out the notion of 
PKC phosphorylation of DAT as an endocytosis requirement and implicating the 
potential involvement of another protein [55].  
  Mitogen activated protein kinases (MAPK) have been shown to regulate DAT 
function and surface expression. Inhibition of MAPK with U0126 or PD98059 
significantly decreased DAT function in both rat striatal synaptosomes and in HEK 293 
cells stably expressing DAT. The decrease in uptake activity in MAPK-inhibited 
conditions was associated with enhanced DAT internalization [56]. Later in 2007 another 




N2A and EM4 cells (HEK 293 cells stably expressing macrophage scavenging receptor). 
The quinpirole treatment also stimulated the activated forms of MAPK and 
phosphoinositide-3 kinase (PI-3 kinase). Inhibition of both these kinases abolished the 
agonist-stimulated increase in DAT uptake activity and surface expression. Acute 
treatment with DA receptor agonists increased DAT surface expression while longer 
treatment times increased internalization [57].  
  Metabolic [32P] labeling and phosphoamino acid analysis in rat striatal slices and 
DAT expressing cell systems have narrowed down the PKC phosphorylation sites to the 
N-terminal 6-serine cluster with a majority of the phosphorylation and a threonine with a 
faint phosphorylation signal at the distal N-terminus of DAT [58] (Fig.6) . Though PKC 
was the extensively studied kinase for DAT phosphorylation, in vitro kinase assays with 
recombinantly expressed N-terminus of DAT (N-DAT) showed increased 
phosphorylation with proline-directed kinases: ERK, PKC, P38, JNK. Gorentla et al 
identified the threonine as a proline-directed phosphorylation site on the DAT N-
terminus, T53 [44]. This proline-directed site is also found conserved in human DAT as a 
serine. The evidence that has accumulated over years that has shown DAT to be 
phosphorylated by different kinases triggered research in trying to understand the impact 
of the phosphorylation on function, surface expression and other properties of DAT.  
  DAT phosphorylation is also affected by psychostimulants like AMPH and 
METH but not COC. In vitro and in vivo treatments of amphetamines stimulate 
phosphorylation of DAT, which is abolished by PKC inhibitors.  This phosphorylation 
was found to be at the serine cluster at the distal N-terminus of DAT as Δ21 DAT, a 




phosphorylation [59]. Some studies have shown that the N-terminus [60] and 
phosphorylation on the N-terminus of DAT are required for AMPH-stimulated efflux 
[61].  CaMKII interaction with the C-terminus of DAT has been demonstrated in both 
heterologous expression systems and in dopaminergic neurons. Interaction of CaMKII 
with DAT C-terminus facilitates phosphorylation of the N-terminus of DAT which is 
required for AMPH-stimulated DA efflux. Inhibition of CaMKII or mutation of N-
terminal phosphorylation sites on DAT attenuated both AMPH-stimulated DA efflux and 
MPP+ efflux suggesting the importance of N-terminal phosphorylation for the efflux 
mechanism of AMPH [62,63]. PKC activation by PMA increases DAT-mediated efflux 
indicating either a direct role for DAT phosphorylation in efflux or attraction of an 
interacting partner that facilitates efflux [64]. Though AMPH induces efflux and 
stimulates DAT phosphorylation, METH has been observed to have a stronger effect than 
AMPH [65]. All these studies imply that AMPH-stimulated DAT phosphorylation could 
be a key mechanism responsible for the psychostimulant action and of the strong 
reinforcement characteristic of this drug. 
Proline-directed phosphorylation 
!
  Phosphorylation of a serine/threonine preceding a proline (proline-directed 
phosphorylation site) renders an additional structural change to the protein [66] and is 
predicted to impact the structure and function of the protein (Fig.7). Prolyl isomerases 
(PPIases) catalyze the conversion of cis/trans conformation of Ser/Thr-Pro peptides. Pin1 
(Protein interacting with NIMA), a parvulin family member, specifically catalyzes the 










Figure 7. Isomerization of proline-directed phosphorylation sites by Pin1 
Peptidyl prolyl isomerase, Pin1, catalyzes the cis-trans isomerization of phosphorylated-
Thr-Pro (pT-P) allowing the dephosphorylation by conformation-specific phosphatases. 
Pin1 stabilizes the cis and trans conformations of pT-P of the protein, which are predicted 
















Image adapted from K. P. Lu and X. Z. Zhou, 2007, The prolyl isomerase PIN1: a pivotal 
new twist in phosphorylation signalling and disease., Nat. Rev. Mol. Cell Biol., vol. 8, no. 
11, pp. 904–16, with permission [68]. 
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pSer/Thr-Pro-containing peptides is intrinsically slow and requires the activity of the 
isomerases.  
T53 is the only reported proline-directed phosphorylation site on the DAT N-
terminus that is phosphorylated in vitro by proline-directed kinases such as ERK, JNK 
and P38 [44]. The importance of T53 in regulating DAT function was recently 
demonstrated [69]. The role of N-terminal residues in regulating DAT function was also 
reported in other studies [70] [71].  
Pin1-catalyzed cis/trans isomerization is crucial as it allows the 
dephosphorylation by conformation-specific phosphatases such as PP2A (Fig.7). This 
was demonstrated in the hyperphosphorylated tau protein. Pin1 facilitates the 
dephosphorylation of hyperphosphorylated tau protein by PP2A showcasing the presence 
of a post-phosphorylational regulatory step that restores the function [72] [73]. This 
indicates an additional regulatory step for proline-directed phosphorylation sites that 
might dictate DAT function or subcellular localization.  
Purpose of the current study 
!
DAT phosphorylation and function has been shown to be regulated by 
psychostimulant drugs [64,74], [76–78]. Previous studies from our lab indicated a 
differential regulation by psychostimulant drugs on DAT function and phosphorylation 
[74], [77]. While direct regulation of DAT by PKC has been reported [45], [78] , MAPK 
regulation of DAT via dopamine 2 receptors (D2Rs) was reported [56], [57]. In this study 
we specifically investigated the effect of psychostimulant drugs and DA on pT53 in a 




help in understanding the role of psychostimulant action on pT53 and direct regulation of 
DAT by MAPK. Also, we designed our experiments to test for post-phosphorylational 
regulation at pT53 and its effect on DAT function using the Pin1 inhibitor, juglone (Jug). 
These results will increase our understanding of the additional pathways regulating DAT 






















Male Sprague Dawley rats (175-300g) were purchased from Charles Rivers Laboratories 
(Wilmington, MA) and maintained in compliance with the guidelines established by the 
University of North Dakota Institutional Animal Care and Use Committee and the 
National Institutes of Health.   
Reagents 
!
Protein A Sepharose beads, and High Range Rainbow Molecular Weight Markers were 
purchased from GE Healthcare Life Sciences (Piscataway, NJ). (-)-Cocaine, d-
amphetamine, (+)-methamphetamine, dopamine, and benztropine were purchased from 
Sigma Aldrich (St. Louis, MO). Phorbol-12 myristate-13 acetate (PMA) and Okadaic 
Acid (OA), and Juglone were purchased from Calbiochem/EMD Biosciences (La Jolla, 
CA). Ez-Link Sulfo-NHS-SS-Biotin and immobilized Neutravidin Beads were obtained 
from Pierce Chemical (Rockford, IL). Complete Mini Protease Inhibitor was purchased 
from Roche Applied Science (Indianapolis, IN). All other chemicals were purchased 








The Beckman Avanti J-25 was used for synaptosomal preparation. The Beckman J6-MI 
swinging bucket rotor was used for crosslinking Protein A Sepharose beads. A 
refrigerated Beckman Microfuge R or a bench top Microfuge were used to pellet cells 
and for immunoprecipitations. 
Electrophoresis 
!
SDS-PAGE was performed using Bio-Rad Mini-Protean III electrophoresis apparatus and 
proteins transfers to PVDF were performed using Bio-Rad Mini trans blot electrophoresis 
transfer cell. A Gibco/BRL Life Technologies 250 EX power supply was used to control 
both Bio-Rad electrophoresis and Bio-Rad protein transfer apparatus. 




 (Lewis lung carcinoma porcine kidney) cells stably expressing rDAT were 
maintained in a Nuair 2700-30 water-jacketed CO2 incubator and handled in a Nuair 
Class II type A/B3 laminar flow hood. Synaptosomal preparations for uptake and efflux 









T53 Phosphorylation assay in rDAT LLC-PK1 cells 
!
LLC-PK1 cells stably expressing WT rDAT were maintained in α-minimum essential 
medium supplemented with 10% fetal bovine serum, 2 mM L- glutamine, 200 µg/ml 
G418, and 1 X penicillin/streptomycin in an incubation chamber with 5% CO2, 95% O2 at 
37°C. Cells were plated in either 6 or 12 well plates and grown to 80% confluence. Cells 
were washed twice with 2 ml or 1 ml of Kreb’s-Ringer HEPES (KRH) buffer (25 mM 
HEPES, 125 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.3 mM CaCl2, 1.2 mM MgSO4, 
5.6 mM glucose, pH 7.4). Cells were treated with 10 µM d- amphetamine, BZT, 100 µM 
cocaine, 1 µM OA, 1 µM PMA or vehicle for 30 min at 37° C. BZT, d-amphetamine, (-)-
cocaine, were prepared in distilled/deionized water, OA and PMA were prepared in 
DMSO with a final DMSO concentration maintained below 1%. Each condition was 
performed in duplicate. Cells were immediately placed on ice and washed with ice-cold 
KRH twice to remove the drugs. 300 µl of RIPA with protease inhibitor was added to 
each well and solubilized on ice for 20 min with shaking. The cell lysates were 
centrifuged at 15,000 x g for 30 min at 4°C. The supernatants were collected and 
subjected to SDS-PAGE and the proteins were transferred to PVDF membrane. The 
membrane was immunoblotted with a phospho-specific antibody (1:1000 dilution in 3% 
BSA blocking buffer) developed against T53 on DAT (pT53 Ab) [69]. Total DAT in the 
corresponding samples was analyzed by immunoblotting samples with DAT specific 




epitope 16 on the N-terminus on DAT (MAb16) [79]. Parental cells not expressing DAT 
were used as negative control. 
Striatal synaptosomal preparation 
!
 Striatal synaptosomes were prepared using male Sprague Dawley rats (175–300 g) [80]. 
In brief, animals were decapitated and the striatum was removed and weighed. The striata 
were suspended in cold sucrose phosphate (SP) buffer (10 mM Na2HPO4, 0.32 M 
sucrose, pH 7.4) and homogenized in a Teflon-glass homogenizer. The homogenate was 
centrifuged at 3000 × g for 3 min at 4°C. The resulting supernatant was further 
centrifuged at 17000 × g for 12 min at 4°C. The synaptosomal pellet was then re-
suspended in 0.32 SP buffer at 20 - 50 mg/ml of original wet weight (OWW) for 
phosphorylation, uptake and efflux assays. 
Phosphorylation, Immunoprecipitation and Immunoblot analysis in striatal synaptosomes 
!
The synaptosomes were aliquoted into individual tubes and treated with vehicle or 10 µM 
d-amphetamine, (+)-methamphetamine, dopamine, 5µM juglone or indicated 
concentration for 30 min or the indicated time at 30°C. Each condition was performed in 
duplicate. The reaction was quenched by adding 1X sample buffer. The samples (50 µl) 
were then immunoprecipitated with 50% slurry of pT53 Ab crosslinked protein A 
sepharose beads at 4°C overnight and the beads were washed with IP buffer (phosphate 
buffered saline, pH 7.4, plus 0.05% SDS, 0.1% Triton X-100) 4 times. The samples 
eluted with 1X sample buffer at 37°C were subjected to SDS-PAGE electrophoresis and 
transferred to PVDF. The immunoblot was then developed with MAb16 and pT53Ab for 




Dopamine uptake in striatal synaptosomes 
!
For uptake assays, synaptosomes were treated with the indicated concentration of Jug or 
vehicle prior to the assay for 30 min or indicated times at 30°C. The DMSO 
concentration was maintained ≤ 1%. Transport was initiated by adding the synaptosomes 
into tubes containing modified-Krebs phosphate buffer (126 mM NaCl, 4.8 mM KCl, 16 
mM potassium phosphate, 1.4 mM MgSO4, 10 mM glucose, 1.1 mM ascorbic acid, and 
1.3 mM CaCl2; pH 7.4), and [3H]DA to a final concentration of 1 nM. Uptake was carried 
out in quadruplicate for 3 min at 30°C using 100 µM (−)-cocaine to define non-specific 
uptake. Transport was stopped by the addition of 5 ml ice-cold SP buffer 
and synaptosomes were harvested using a Brandel tissue harvester and Whatman GF/B 
filters pre-soaked for 1 h in a 0.05% polyethyleneimine. Bound radioactivity was 
quantified by liquid scintillation counting. 
Efflux measurement in striatal synaptosomes 
!
Synaptosomes were loaded with [3H]DA and incubated at 30°C for 5min. The extra-
synaptosomal [3H]DA was removed by centrifugation of the synaptosomes at 17000 x g 
for 12 min at 4°C and the supernatant was discarded. The synaptosomal pellet was 
reconstituted with SP buffer and treated with indicated concentration of juglone for the 
indicated times at 30°C. The synaptosomes were again spun down and the supernatant 
was counted for radioactivity. Synaptosomes treated with 100 µM (−)-cocaine along with 





In vivo analysis treatment of male Sprague-Dawley rats 
!
Male Sprague-Dawley rats were subcutaneously injected with saline or METH (15 
mg/kg) or COC (15 mg/kg) and the treated animals were caged separately. The animals 
were decapitated after the treatment times and brain dissection was performed to remove 
the striata which were placed in ice-cold SP buffer.  
Striatal membrane preparation 
!
Striatal membranes were prepared as described previously [59]. Briefly the membranes 
were prepared using polytron and the homogenate was then centrifuged at 12000 x g for 
12 min at 4°C. The membranes were then immunoprecipitated with protein-A sepharose 
cross-linked with pT53 Ab overnight at 4°C to avoid any non-specific immunostaining. 
The eluted sample is then subjected to SDS-PAGE followed by transfer to PVDF 
membrane. The membrane is then immunoblotted with MAb16 to analyze for T53 
phosphorylation (pT53).  
ELISA 
!
For the bait, recombinantly expressed and purified NDAT (10µg/ml) and commercially 
available recombinant Pin1 (10µg/ml) from were coated on ELISA plates overnight at 
4°C. The wells are then blocked with commercially available blocking solution at 4°C. 
The solution containing prey either NDAT (10µg/ml) or Pin1 (10µg/ml) were incubated 
in the appropriate well. The wells were incubated with MAb16 for NDAT or Pin1 
polyclonal Ab and the interaction is detected by incubating with 1mg/ml PNPP substrate. 






The immunoblots were quantified by densitometry (LumiAnalyst software) and the 
averaged values were statistically analyzed by student’s t-test or ANOVA. The graphs 









Physiological regulation of DAT T53 phosphorylation 
!
!!! To investigate the physiological regulation of pT53, LLC-PK
1
 cells stably 
expressing rDAT were treated with the protein phosphatase inhibitor, okadaic acid (OA) 
and PKC activator, PMA. Immunostaining with pT53 Ab revealed that T53 undergoes 
basal phosphorylation and both OA (178 ± 15%, p<0.005) and PMA (140 ± 13%, p<0.05) 
treatments stimulate pT53 (Fig.8). This indicates the dynamic regulation of T53 under 
physiological conditions. Immunostaining with MAb16 displayed similar DAT levels in 
the corresponding samples indicating that the treatment had no impact on total DAT 
protein. The parental LLC-PK
1
 cells displayed no immunostaining with both pT53Ab and 
MAb16 indicating the specificity of the antibodies to DAT [69]. 




  To identify the protein phosphatase that dephosphorylates pT53 on DAT, we 
performed an OA dose response treatment in rDAT LLC-PK
1
 cells and the cell lysates 
were analyzed with pT53 Ab or MAb16. An OA dose range of 0.1 nM to 1000 nM was 












Figure 8. Kinase and phosphatase modulators stimulate pT53 
Cells expressing rat DAT were treated with 1 µM OA, 1 µM PMA or vehicle (Basal) for 
30 min at 37°C.  Blots were probed with probed with pT53Ab (top) or MAb16 Ab 
(bottom). The histogram indicates the quantification of pT53 signal induced by OA and 
PMA (means ± S.E.), n=3, ***p value <0.0005, t-test. Solubilized DATs were resolved 

















      
                           
 
                          










































































Figure 9. Dose response of OA-stimulated DAT pT53 
rDAT LLC-PK1 cells were treated with increasing doses of OA for 30 min at 30°C.  
Solubilized DATs were resolved by SDS-PAGE and transferred to PVDF. Blots were 
probed with pT53Ab (top) to detect phosphorylation and MAb16 (bottom) to detect total 
DAT. The graph indicates T53 phosphorylation normalized to total DAT with respect to 
the dose of OA.  Arrows indicate the IC50 values of the specified phosphatases. n=3, p< 
















                              









or no effect at lower doses of OA. According to the dose response curve the IC50 of OA 
for T53 on DAT was indicated to be in the range of phosphatase PP1 (0.15 nM) (Fig.9).  
Under our experimental conditions no visible effect was observed at IC50 values 
corresponding to other phosphatases indicating PP1 as the potential phosphatase 
dephosphorylating T53.  
Psychostimulants differentially affect T53 phosphorylation on DAT 
!
  Psychostimulant drugs have been demonstrated to affect DAT function by 
regulating DAT phosphorylation [77] [59]. To examine the effects of psychostimulant 
DAT blockers and substrates on DAT pT53 levels, LLC-PK
1
 cells stably expressing rDAT 
were treated with indicated drugs for 30 min using the phosphatase inhibitor, OA as 
positive control (Fig.10). Cell lysates were immunoblotted with pT53 Ab, a phospho-
specific antibody to detect phosphorylation of DAT specifically at T53 [69]. Western blot 
analysis revealed that DAT displays pT53 under basal conditions as indicated in lane 1. 
We observed that the psychostimulant substrate AMPH (lane 4) significantly stimulated 
the DAT pT53 152 ± 9% of basal, (p<0.05) (Fig.10). Inhibition of protein phosphatases 
with OA resulted in significant accumulation of pT53 levels, 177 ± 19% of basal, 
(p<0.005) (Fig. 8 and 9). Interestingly, DAT blockers COC (110 ± 15% of basal) (lane2) 
and BZT (93.5 ± 12.5% of basal) (lane 3) had no effect on pT53. The inability of both 
psychostimulant (COC) and non-psychostimulant (BZT) DAT blockers to stimulate pT53 
suggests that the stimulation of pT53 might be a substrate-specific effect. These results 
demonstrate a differential response of psychostimulant substrates and blockers on DAT 













Figure 10. Amphetamine stimulates phosphorylation at T53 on DAT 
rDAT LLC-PK
1
 cells were treated with vehicle or 10 µM AMPH, BZT or 100 µM COC 
or 1 µM OA for 30 min and cell lysates were immunoblotted with anti-pT53 Ab to detect 
phosphorylation or MAb 16 to detect total DAT.  The histogram shows pT53 staining 






































                       
 
                              













 observed to be unaffected by the treatment conditions. 
Psychostimulant substrates stimulate DAT T53 phosphorylation in a cocaine-dependent 
manner 
 
  As DAT uptake blockers displayed no stimulatory effect on pT53 (Fig.10), we 
questioned if stimulation of pT53 is a substrate-specific phenomenon. To investigate this, 
we treated rDAT LLC-PK
1
 cells with the psychostimulant substrates AMPH, METH and 
the endogenous substrate, DA for 30 min. The psychostimulant substrates stimulated 
pT53 significantly, METH (159 ± 24% of basal, p<0.005); AMPH (142.4 ± 8% of basal, 
p<0.05) as shown in Fig. 11. The endogenous substrate, DA showed a trend towards 
increase in pT53 levels (125 ± 6% of basal) however, it was not found to be statistically 
significant. These data indicated that the increase in DAT pT53 is a substrate-specific 
phenomenon, with a significantly stronger effect observed with psychostimulant 
substrates. 
  Amphetamines are lipophilic in nature and in addition to being transported via 
DAT into cell, they can also diffuse through plasma membrane [81]. The next question 
we addressed was, if the effect of AMPH on pT53 is a DAT-mediated effect. We 
addressed this question by pretreating rDAT LLC-PK
1
 cells with 100 µM (-) cocaine, 
followed by treatment with 10 µM AMPH therefore, preventing the entry of AMPH via 
DAT. We observed the stimulatory effect of AMPH on pT53 (142 ± 8%, p<0.005) 
(Fig.10 & 11). Similar to the observation in Fig.10, COC treatment alone on rDAT LLC-
PK
1





















Figure 11. Psychostimulant substrates stimulate pT53 
rDAT LLC-PK1 cells are treated with vehicle or 10 µM of the indicated drugs for 30 min 
at 37°C. The cell lysates were immunoblotted with anti-pT53 (top) to detect 
phosphorylation or MAb 16 (bottom) to detect total DAT. Histogram indicates the T53 
phosphorylation normalized to total DAT (means ± S.E.). n=4, p<0.01 (**), <0.05 (*), 




































                
 




































Figure 12. Cocaine blocks amphetamine stimulated DAT pT53 
rDAT LLC-PK
1
 cells were treated with vehicle or 10 µM AMPH for 30 min in the 
absence or presence of 100 µM COC. COC pre-treatment was performed for 10 min 
followed by additional 30 min with AMPH, and cell lysates were immunoblotted with 
anti-pT53 to detect phosphorylation or MAb16 to detect total DAT. The histogram shows 
the pT53 staining normalized for total DAT (means ± S.E.). n≥3, ***p value 













                      









four independent experiments, each performed in duplicate, we observed that the AMPH 
effect on pT53 was blocked when the cells were pre-treated with COC, displaying 97 ± 6 
% of the basal pT53 level. Perturbing the entry of AMPH into the cell through DAT, but 
not the diffusion through plasma membrane completely abolished the AMPH effect on 
pT53. This showed that stimulation of pT53 by AMPH is a DAT-mediated effect. 
Native tissue response differs from heterologous system in amphetamine effect 
!
Psychostimulant substrates stimulate pT53 in a time-dependent fashion in cells 
!
  To analyze the time dependence of AMPH and METH on DAT pT53, we treated 
LLC-PK
1  
rDAT cells with 10 µM AMPH or METH for the indicated time points and the 
cell lysates were assayed for pT53. AMPH significantly increased pT53 at 30 min 
(142±7.8% of basal, p<0.005) treatment and pT53 level was sustained for atleast 60 min 
(139±7.6% of basal, p<0.05) (Fig.13A). Shorter time points tested (2, 5, 10, min) did not 
show a significant effect (not shown). METH treatment stimulated a small yet significant 
increase in pT53 at 2 min (121±7.1% of basal, p<0.05), and 30 min METH treatment 
stimulated pT53 (131±4% of basal, p<0.005) (Fig.13B) to levels similar to that of AMPH 
in cells.   
Time course of METH-stimulated pT53 in rat striatal synaptosomes 
!
  Next, we sought to investigate the time dependence of stimulated pT53 levels in 
native tissue. We performed a time course of METH treatment under ex vivo conditions, 
in rat striatal synaptosomes. In contrast to, LLC-PK
1
 cells, METH treatment in rat striatal 













Figure 13. Time course of amphetamine stimulated pT53 
rDAT LLC-PK
1
 cells treated with vehicle or 10µM AMPH (A) or METH (B) for the 
indicated times, were immunoblotted with pT53 Ab to detect phosphorylation or MAb 16 
to detect total DAT.  The graphs indicate summary of pT53 normalized to total DAT 
(means ± S.E.). n≥3, **p value <0.005 relative to basal, *p value < 0.05 relative to basal, 

















     




























Figure 14. Methamphetamine stimulates pT53 in rat striatal synaptosomes 
Rat striatal synaptosomes were isolated and treated with 10 µM METH for the indicated 
times at 30°C.  Solubilized DATs were resolved by SDS-PAGE and transferred to PVDF.  
Blots were probed with pT53Ab. Graph indicates T53 phosphorylation normalized to 
total DAT (means ± S.E.). n≥3, **p value<0.005, *p value<0.05 relative to basal, one-






























p<0.005) after treatment and this increase was also observed at 10 min (128 ± 3% of 
basal, p<0.005) (Fig.14), and the pT53 level sustained atleast 20 min (121 ± 7%) (data 
not shown). This indicates psychostimulant drugs impart their effect on pT53 faster in 
native tissue when compared with the heterologous expression system. 
Methamphetamine but not cocaine stimulates pT53 in vivo 
!
To investigate the differential regulation of psychostimulant drugs on pT53 in vivo, we 
subcutaneously injected male Sprague-Dawley rats with 15 mg/kg METH; or COC or 
saline for 30 min (Fig.15). After 30 min, the animals were then decapitated to remove the 
striata and the striatal membranes were analyzed for pT53 levels and total DAT levels. 
The saline injected animal displayed basal pT53 levels. COC-injected animals displayed 
no effect on pT53 levels (Fig.15) similar to our results observed in the heterologous 
expression system (Fig.13). METH-treated animals displayed a significant stimulation of 
pT53 (Fig.15) compared to saline and COC injected animal. This further confirms the 
differential regulation of psychostimulant drugs on pT53 both in a heterologous 
expression (Fig.13) system and in vivo. MAb16 immunostaining displayed similar DAT 
levels in saline and drug-injected animals indicating that treatment had no effect on total 
DAT levels. 
Methamphetamine time course in vivo 
!
To further understand the effect of METH on pT53, we performed a time course of 
METH treatment in vivo in male Sprague-Dawley rats. The animals were subcutaneously 
(SC) injected with METH (15mg/kg) or saline and caged individually until decapitation. 



















Figure 15. Methamphetamine but not cocaine stimulates pT53 in vivo 
Male Sprague-Dawley rats were subcutaneously injected with 15mg/kg of 
methamphetamine (METH), 15 mg/kg cocaine (COC)  or saline for 30 min. The animals 
were decapitated and the brains were dissected to make striatal membranes which then 
were subjected to immunoprecipitation with protein-A-sepharose cross-linked with pT53 
Ab and the eluted sample was resolved by SDS-PAGE and transferred to PVDF.  Blots 
were probed with MAb16. Total DAT levels were determined by directly blotting lysates 
with MAb16. The DAT pT53 was normalized to total DAT levels.  Histogram indicates 
the quantification of the immunoblots, (means ± S.E.). n=3, *p value<0.05 relative to 



































Figure 16. Methamphetamine stimulates pT53 in vivo in a time-dependent manner 
Male Sprague-Dawley rats were subcutaneously injected with 15mg/kg of 
Methamphetamine (METH) for the indicated time points. The animals were decapitated 
and the brains were dissected to make striatal membranes which then were subjected to 
immunoprecipitation with protein-A-sepharose cross-linked with pT53 Ab and the eluted 
sample was resolved by SDS-PAGE and transferred to PVDF.  Blots were probed with 
MAb16. The DAT pT53 was normalized to total DAT levels.  Histogram indicates the 
quantification of the immunoblots, (means ± S.E.). n≥3,!**p value<0.005, *p value<0.05 





























dissected to remove the rat striatum and the rat striatal membranes were analyzed for 
pT53 levels. The saline control animals displayed a basal level of pT53 immunostaining 
similar to the rDAT LLC-PK
1
 cells indicating the regulation of pT53 under physiological 
conditions. We observed the stimulation of pT53 levels in METH-injected animals and 
this effect occurred in a time-dependent fashion. The shortest in vivo time point tested 
was 10 min, which displayed a significant stimulation of pT53 at 10 min (119 ± 3%, 
p<0.005). The stimulation of pT53 was further increased at 30 min (129 ± 10%, p<0.005) 
and the increased pT53 was sustained at 60 min (128 ± 10%, p<0.05) (Fig.16) indicating 
the alteration of downstream signaling. The METH-injected animals were observed to be 
visibly hyperactive compared to the saline control.                           
Pin1 inhibitor, juglone, stimulates pT53 in cells and in rat striatal synaptosomes 
!
We hypothesized that Pin1 isomerizes cis-pThr53-Pro54 to trans-pThr53-Pro54 
allowing dephosphorylation by conformation-specific phosphatases. To investigate our 
hypothesis of Pin1 regulation of DAT, we used juglone (Jug), a small-molecule inhibitor 
specific for Pin1. LLC-PK1 cells stably expressing rDAT were treated with Jug or DMSO 
as control and the cell lysates were analyzed for pT53 and total DAT levels. Treatment of 
LLC-PK1 cells stably expressing rDAT with Jug significantly increased pT53 at both 5 
µM (162 ± 13%, p< 0.005) and 10 µM (128 ± 12%, p<0.05) (Fig.17) compared to the 
control conditions. OA used as positive control stimulated pT53 120 ± 5%, p<0.005 
compared to control. Jug-stimulated pT53 represents the accumulation of the cis-














 cells or (B) rat striatal synaptosomes were treated with indicated 
concentrations of Pin1 inhibitor, Juglone for 30 min at 30°C. The samples were then 
solubilized with sample buffer and DAT was resolved with SDS-PAGE and transferred to 
PVDF membrane. The pT53 signals were identified with pT53 Ab and total DAT levels 
with MAb16. Histogram indicates phospho-T53 signals normalized to total DAT (means 
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Figure 17. Pin1 regulates dephosphorylation of DAT T53 in LLC-PK1 rDAT cells and in 






preferring phosphatases. This indicates post-phosphorylation regulation of DAT by the 
prolyl isomerase, Pin1. 
We investigated if Pin1 exhibited similar regulation on DAT in native tissue. To 
analyze that, we treated rat striatal synaptosomes with Juglone or DMSO and measured 
pT53 levels. The DMSO control revealed basal-level pT53, which was significantly 
increased in the presence of Jug, both at 5 µM, 117 ± 3 %, p<0.05 and at 10 µM, 121 ± 4 
%, p <0.005 compared to control. Activation of protein kinase C (PKC) by PMA, used a 
positive control also stimulated pT53 133 ± 9 %, p<0.005, compared to control (Fig.17). 
The total DAT levels were unaffected by the treatment conditions. This indicates the Pin1 
regulates DAT pT53 in heterologous expression system and in rat striatal synaptosomes. 
Our data reveals a novel pathway of DAT regulation by Pin1 via T53 phosphorylation. 
Juglone stimulates [3H]DA efflux from rat striatal synaptosomes 
 
We next explored the effect of Pin1 regulation on DAT function. Rat striatal 
synaptosomes were treated with Jug and analyzed for basal [3H]DA efflux. We observed 
a basal [3H]DA efflux in synaptosomes treated with DMSO. Jug treated rat striatal 
synaptosomes exhibited a significant increase in [3H]DA efflux both at 5 min (211 ± 
25%, p<0.005) and 15 min (203 ± 23%, p<0.005) (Fig.18) treatment time points 
compared to the control conditions. The efflux observed was blocked by COC and 
occurred in the absence of efflux-stimulating substances like amphetamine (AMPH). This 
is the first observation to demonstrate a significant increase in basal efflux by a cis-trans 
prolyl isomerase inhibitor. We observed that under the same conditions, DAT uptake 




shown) suggesting that Jug effect on DAT function could potentially be altering DAT 
conformation to an efflux promoting state.  
Juglone stimulates pERK 
!
We next explored the pathway of Jug-stimulated efflux in rat striatal 
synaptosomes. Jug stimulates pT53 (Fig.17) in rat striatal synaptosomes and T53 has 
been demonstrated to be a substrate for proline-directed kinases such as ERK [44]. We 
analyzed the rat striatal synaptosomal sample for increase in phosphorylated ERK 
(pERK). The rat striatal synaptosomes revealed a basal pERK signal, which was 
significantly increased in rat striatal synaptosomes treated with Jug for both 5 min 
(196%±22, p<0.005) and 15 min (175±23%, p<0.05) compared to DMSO treated control 
(Fig.19). This suggests that Pin1 also regulates the function of ERK by cis-trans 
isomerization of proline-directed phosphorylation sites on ERK required for its 
activation. Immunostaining with ERKAb revealed that total ERK levels were unaffected 
under the experimental conditions indicating that Jug stimulates pERK without affecting 
the total ERK levels. This suggests that Jug-stimulated [3H]DA efflux could be achieved 
via pERK mediated phosphorylation of T53 on DAT.  
Pin1 interacts with the N-terminus of DAT 
!
 Our next step was to investigate the interaction between Pin1 and DAT. We 
recombinantly expressed the N-terminus of DAT (N-DAT) in E.coli and purified the 
peptides as described in [44]. ELISA was performed using N-DAT as bait and 
recombinant Pin1 as prey and vice-versa. The colorimetric density was used as a 




interaction between N-DAT and Pin1, occurs in a dose-dependent manner (data not 
shown). Our ELISA data demonstrates the prolyl isomerase, Pin1 as a new interaction 
partner of DAT (Fig.20), which regulates the mechanism of DAT mediated [3H]DA 



































Figure 18. Juglone stimulates [3H]DA efflux in rat striatal synaptosomes 
Rat striatal synaptosomes were loaded with [3H]DA for 5 min at 30°C followed by 
treatment with Jug for 5 and 15 min at 30°C. The synaptosomes were immediately 
centrifuged at 4°C at 17000xg for 12 min and the supernatant was analyzed for [3H]DA 
efflux. Jug significantly increased [3H]DA efflux from rat striatal synaptosomes at both 5 







































Figure 19. Juglone activates ERK 
Jug-treated rat striatal synaptosomes were immunoblotted with pERK Ab and ERK Ab to 
analyze the levels of activated ERK and total ERK respectively. Inhibition of Pin1 by Jug 
significantly increased pERK compared to control, ** p<0.005 and * p<0.05, n (4), one-
way ANOVA, tukey’s post-hoc test. Histogram demonstrates the quantification of pERK 








































Figure 20. Pin1 interacts with the N-terminus of DAT 
ELISA was performed as described in methods. Briefly, recombinantly expressed N-
terminus of DAT (N-DAT, 10 µg/ml) was used as bait and recombinant Pin1, (10 µg/ml) 
was used as prey. PNPP was used as substrate for colorimetric analysis. The absorbance 































Psychostimulant substrate regulation of DAT T53 phosphorylation 
!
 Our study demonstrates the differential effect of psychostimulant drugs on pT53, 
a proline-directed phosphorylation site on the DAT N-terminus. Psychostimulant 
substrates like AMPH and METH were observed to increase pT53 in a heterologous 
expression system, rat striatal preparations and under in vivo conditions. Uptake blockers 
tested including COC, BZT were not capable of this stimulatory effect nor did they affect 
basal pT53 levels. Although AMPH and METH have been shown to stimulate PKC-
mediated DAT phosphorylation, the majority of which occurs at the serine cluster at the 
N-terminus [59], this is the first evidence to demonstrate a differential effect of 
psychostimulant substrates and blockers on the proline-directed phosphorylation site on 
DAT. Proline-directed kinases such as ERK regulation of DAT activity via dopamine 
receptor mediated mechanisms [56], [57] have been shown. However, our findings unveil 
a direct regulation of DAT by proline-directed kinases via T53.   
 We have also identified a novel regulatory pathway of DAT function by a 
peptidyl prolyl cis-trans isomerase, Pin1. A small molecule inhibitor of Pin1, Jug 




synaptosomes. In addition, we also observed that Pin1 regulates the efflux mechanism of 
DAT in rat striatal synaptosomes potentially via direct interaction between N-DAT and 
Pin1. 
 Inhibition of phosphatases by OA has always produced the highest level of DAT 
phosphorylation indicating the continuous activity of the physiological system to 
maintain a non-phosphorylated DAT state. In attempts to identify the phosphatase acting 
at T53 we performed dose response of OA in rat striatal synaptosomes and a heterologous 
cell system. OA dose response performed in rat striatal synaptosomes and the 
heterologous system both indicated PP1 to be the likely phosphatase involved in T53 
regulation. No effect was seen at lower doses of OA that corresponds to inhibit PP2A 
ruling out PP2A as the phosphatase acting at T53 under the conditions we tested. PP1 has 
been shown to be the primary phosphatase involved in DAT phosphorylation regulation 
although PP2A inhibitor also showed a significant increase in DAT phosphorylation [82]. 
It is possible that our experimental conditions or detection by western blot was not 
sensitive enough to detect an effect present at lower doses of OA. Further research with 
specific phosphatase inhibitors is required to approach this aspect.  
 The AMPH effect on DAT T53 phosphorylation is either due to binding to or 
transport through DAT as COC blockade of DAT prior to AMPH treatment in LLC-PK
1
-
rDAT abolishes the AMPH effect. This is in accordance with the METH effect on the 
DAT phosphorylation which was also blocked by COC pre-treatment [59]. This indicates 
that the AMPH effect on DAT phosphorylation is not due to diffusion of AMPH through 
the plasma membrane but DAT-dependent. COC by itself did not influence both overall 




 The time dependence of pT53 stimulated by AMPH in a heterologous expression 
system and in striatal synaptosomes produced interesting results. AMPH treatment of 
LLC-PK
1
- rDAT showed a significant increase in T53 phosphorylation only after 30 min 
treatment and was sustained until 60 min. The shorter time points (5-20 min) did not 
affect the basal T53 phosphorylation. However in rat striatal synaptosomes METH 
caused a significant increase in DAT T53 phosphorylation as short as 60 sec. This is the 
first evidence so far for a rapid phosphorylational stimulation by a psychostimulant. 
METH effect on T53 phosphorylation remained significant until 10 min and the next time 
point tested (20 min) does not show a significant effect. It is interesting to note that the 
METH effect on overall DAT phosphorylation which was observed to be on the serine-
cluster of the N-terminus is significant only at 10 and 15 min treatment [59]. METH 
induced DAT T53 phosphorylation might be one of the initial steps followed by serine-
cluster phosphorylation. Since the METH-effect on T53 is instantaneous, it might be 
affecting the transport kinetics or interaction of DAT with other proteins that facilitate or 
affect function of DAT downstream. 
We have previously reported in both the heterologous expression system and in 
rat striatal tissue that, T53 displays basal level phosphorylation which is stimulated in the 
presence PMA and OA [69] and by psychostimulant substrates as indicated in our current 
study (Fig.1, and 6).  Our previous studies revealed that T53A rDAT (phosphorylation-
deficient mutant) and T53D rDAT (phospho-mimetic mutant), had impaired [3H]DA 
uptake activity compared to WT rDAT. Also, both T53A rDAT and T53D rDAT 
displayed no detectable AMPH-stimulated [3H]MPP+ release [69]. The similar functional 




imparted by the phosphorylation rather a potential conformational change associated with 
the pT53 that is crucial for the DAT function. Another N-terminal mutant, T62D DAT 
has been reported to display altered DA uptake and efflux indicating the structural and 
functional importance of the N-terminus [70]. 
 Amphetamines are also known to impact the surface expression of DAT in a 
biphasic manner, which was observed to be cocaine-sensitive. In both rat striatal 
synaptosomes and a cell system treated with AMPH increased the surface expression of 
DAT within 30-60 sec and remained till 60 sec along with an increase in efflux [41], [83] 
but, AMPH treatment for 30 min decreased the surface expression of DAT [40]. METH- 
induced T53 phosphorylation that fades at later time points might be associated with the 
biphasic phenomenon observed in the regulation of surface expression of DAT by 
AMPH. 
 Neuronal proteins like syntaxin 1A (Syn 1A) have been found to affect DAT 
function and phosphorylation. Treatment of Syn 1A protease Botulinum Neurotoxin C 
(BoNT/C) increases DAT phosphorylation in rat striatal tissue along with an increase in 
uptake [35].  Syn 1A interacts with the N-terminus of DAT (1-33 aa of DAT) which is 
stimulated in the presence of AMPH [36]. Expression of Syn 1A in hDAT expressing 
cells potentiated AMPH-stimulated efflux. Interestingly, inhibition of CAMKII, the 
activity of which was observed to be required for AMPH-stimulated efflux [62], 
abolished the Syn 1A stimulated AMPH efflux. Such events are also observed in other 
transporters like NET. The AMPH-stimulated association and surface expression of Syn 
1A with NET was inhibited with CAMKII inhibitor [75]. This suggests the AMPH 




transporters to further regulate transporter function and surface expression. AMPH- 
induced T53 phosphorylation on DAT might also be following a similar mechanism 
although further research is required to address if any protein associations are affected. 
 Recombinantly expressed N-DAT was phosphorylated by PKC, PKA and proline- 
directed kinases like ERK, JNK and p38. Phosphoamino acid analysis of rDAT indicated 
that T53 was strongly phosphorylated by proline-directed kinases like ERK, JNK and p38 
[44]. Our attempts to identify the proline-directed kinase involved in regulation of T53 
phosphorylation in striatal synaptosomes did not provide supporting results. Though the 
inhibitors used were membrane permeable, we assume that the inhibitors were not 
accessible in the treatment time or the western blot employed was not sensitive to detect 
the effects. However it is noteworthy to mention that PKC activator PMA treatment both 
in heterologous system and rat striatal synaptosomes stimulated the T53 phosphorylation 
significantly. 
Post-phosphorylation control of DAT function by peptidyl prolyl cis-trans isomerase, 
Pin1 
!
In this study, we identified a novel regulatory pathway of DAT by the peptidyl 
prolyl cis-trans isomerase Pin1, potentially dictating the cis-trans isomerization of pT53 
on the N-terminus of DAT. This is the first study to show DAT regulation by Pin1, 
which, has been associated with several pathological conditions including cancer and 
Alzheimer’s disease. 
  Pin1 has been demonstrated to catalyze the isomerization of pSer/Thr-Pro 




hyperphosphorylated tau (ptau) protein to the trans conformation by Pin1 is required for 
dephosphorylation, as phosphatases like PP2A have been shown to prefer trans 
configuration [72]. Consistent with these studies, our data revealed that inhibition of Pin1 
using juglone (Jug), thereby preventing cis to trans isomerization, significantly increased 
the pT53 on DAT in both a heterologous expression system and in rat striatal tissue. The 
increase in pT53 observed was in the absence of any stimulating conditions like kinase 
activators or phosphatase inhibitors or psychostimulant substrates. This is the first 
evidence to demonstrate that isomerization of cis-pT53 to trans-pT53 on DAT by Pin1 is 
required for dephosphorylation. Recombinantly expressed N-terminus of DAT (N-DAT), 
phosphorylated by ERK was shown to be resistant to dephosphorylation in vitro by either 
of the phosphatases; PP2A or PP1 [44] consistent with our studies indicating the 
importance of Pin1 catalyzed post-phosphorylation cis-trans conformational change for 
dephosphorylation. The major Ser/Thr phosphatase, PP2A has been shown to interact 
with the N-terminus of DAT [33] in a structural proximity to potentially dephosphorylate 
T53 on the N-terminus of DAT post the Pin1 catalysis. PP2A whose activity on its 
substrates is regulated by Pin1 is known to interact with DAT (site), which leads one to 
speculate a possible effect of Pin1 on DAT.  
Proline-directed kinase, ERK has been shown to regulate DAT uptake via DA 
receptor-mediated mechanism [56], [57]. Treatment of rat striatal synaptosomes with Jug 
caused a tremendous increase in [3H]DA efflux compared to control conditions. This 
increased efflux was observed in the absence of amphetamine, a classic inducer of efflux. 
To our knowledge, this is the first evidence demonstrating a direct role for proline-




that Pin1 catalyzed conformational change is required for the efflux mechanism as our 
previous studies have demonstrated the inability of T53D rDAT to efflux [69]. We 
observed that uptake activity was not altered under the same conditions in rat striatal 
synaptosomes. Jug stimulated efflux in rat striatal synaptosomes was associated with 
significant increase in pERK levels compared to control. This suggests that Jug- 
stimulated efflux observed in the rat striatal synaptosomes potentially could be mediated 
through pERK phosphorylation of T53 on DAT. We are not ruling out the possibility that 
Jug-mediated [3H]DA efflux could be through its action on another neuronal protein as 
Pin1 is known to impact several neuronal proteins like tau, neurofilaments [73], [84], [85] 
and also other kinases like JNK [86]. In addition, T53 on the N-terminus of DAT is 
localized in close proximity to TM1, which forms one of the components of the substrate 
translocation pathway. The pT53 on DAT with its Pin1 catalyzed conformational 
rearrangement, might impact TM1, the substrate permeation pathway component and the 
putative intracellular gate residue R60, thereby potentially influencing DAT function.  
Our ELISA data indicated interaction of Pin1 with N-DAT peptide (Fig.20). This 
suggests that the effect of Jug, on [3H]DA efflux mechanism could be due to the direct 
interaction between Pin1 and N-DAT through isomerization inhibition of pThr53-Pro. 
The AMPH-stimulated efflux has been shown to be affected by several DAT interaction 
partners including Syn 1A, and Flotillin [36][39]. Pin1, by regulating the conformation of 
pThr53-Pro, which also lies in the SH3 domain ligand (P-P-X-X-P), could potentially 
control the interaction of other scaffolding proteins and their regulation of DAT function. 
We observed that the total amount of DAT was not affected by Jug under our 




DAT and diseases 
!
  Dopaminergic signaling has been implicated in several severe pathological 
conditions including ADHD (Attention deficit hyperactive disorder), Schizophrenia, 
Tourette syndrome, bipolar disorder and Parkinson’s disease (PD). DAT polymorphisms 
and death of the dopaminergic neurons are some of the characteristics of a few disease 
states, strongly implying the importance of dopamine homeostasis for normal 
physiological function.  
  In the case of ADHD, a wide set of DAT polymorphisms both in the coding 
regions and the intronic regions have been reported in humans, some of which are 
A559V, R615C, V382A, V55A, E602G hDATs [87][88][89]. A bipolar disorder patient 
and two male siblings diagnosed with ADHD have been reported to have the A559V 
hDAT mutation [90]. These polymorphisms, when cloned into heterologous expression 
systems displayed abnormal DAT functionalities. A559V hDAT displayed a ~ 300% 
increase in spontaneous DA efflux compared to WT DAT. This is referred to as 
anomalous DA efflux (ADE). This indicates the ability of a point mutation to 
significantly affect DAT function potentially by altering the conformation of the substrate 
translocation pathway of DAT.  
  The role of DA D2 auto-receptors (D2R) in mediating the ADE of A559V hDAT 
was demonstrated in 2010 [87]. The ADE displayed by A559V hDAT is thereby 
mediated through D2R activation of CaMKII catalyzed phosphorylation of N-terminal 




[57]. This data demonstrated the involvement of phosphorylation of the DAT N-terminus 
to play a crucial role in pathological conditions. 
  R615C DAT, another ADHD associated mutant had significant reduction in 
surface expression with AMPH-stimulated efflux comparable to WT DAT. 
Coimmunoprecipitation studies demonstrated that R615C DAT-CaMKII complexes were 
significantly enhanced relative to WT DAT-CaMKII complexes. The [32P] Labeling of 
R615C DAT displayed significantly increased basal phosphorylation compared to WT 
DAT [91].  
  Pin1 has been shown to promote APP degradation in AD [92] by inhibiting 
GSK3β thereby reducing the levels of amyloid beta [93]. The notable feature of AD- 
affected neurons is the depletion of soluble Pin1. Pin1 has been shown to facilitate the 
dephosphorylation of tau protein by PP2A showcasing the presence of a post-
phosphorylation regulatory step that restores the function [72][73]. This indicates an 
additional regulatory step for phosphoproteins that might dictate its function or 
subcellular localization.  
Our data culminates to the point that Pin1 regulates the DAT efflux mechanism 
potentially through isomerization of p53 on DAT. All of this experimental evidence 
extends our understanding of psychostimulant substrate regulation of DAT 
phosphorylation at the proline-directed phosphorylation site, T53. Also, we revealed a 
novel pathway of DAT regulation by the isomerase Pin1, which could be exploited to 
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